A molecular model of the F12 biotherapy shows the fold of its polypeptide backbone. Residual T-cell epitopes are mapped onto the structure and colored from white (no epitopes) to dark red (dense overlapping epitopes). The muted red coloring indicates that T-cell epitopes have been broadly silenced in the engineered F12 variant, and this reduced epitope content underlies the molecule’s improved safety and efficacy profile.
The Centers for Disease Control and Prevention (CDC) has prioritized finding effective treatment of methicillin-resistant Staphylococcus aureus (MRSA), one of the most common bacterial pathogens and the single most deadly drug-resistant bacteria in the United States. Now, a new study led by Dartmouth engineering researchers shows promise for an engineered lysin-based antibacterial agent that may enable safe, repeated dosing to treat life-threatening infections by MRSA and other types of S. aureus.
In recent years, lysins—enzymes naturally produced by microbes and associated viruses—have shown potential to treat S. aureus, which can rapidly acquire resistance to other types of antibiotic drugs.
“Lysins are one of the most promising next-generation antibiotics. They kill drug-sensitive and drug-resistant bacteria with equal efficacy, they can potentially suppress new resistance phenotypes, and they also have this laser-like precision,” said Dartmouth engineering professor and corresponding author Karl Griswold.
While there is promise in lysins, development has been slowed due to concerns that they prompt humans’ immune systems to develop antidrug antibodies, which can have negative side effects including life-threatening hypersensitivity reactions.
That’s why the Dartmouth engineering team—which also included researchers in Dartmouth’s computer science department, The Lundquist Institute at Harbor-UCLA Medical Center, Lyticon, and Stealth Biologics—engineered and patented F12, a new lysin-based antibacterial agent. F12 is essentially able to hide from the human immune system (due to T cell epitope deletion), and therefore does not cause the same negative side effects as unmodified, natural lysins.
F12 is the first lysin-based treatment with the potential to be used multiple times on a single patient, making it ideal to treat particularly persistent drug-resistant and drug-sensitive infections. Preclinical studies showed the efficacy of F12 does not diminish with repeated doses, while two other anti-MRSA lysin treatments currently in clinical trials are only designed to be used a single time.
“We have engineered this super potent, super effective anti-MRSA biotherapeutic, and we’ve done it in a way that renders it compatible with and largely invisible to the human immune system. By making it a safer drug, we’ve enabled the possibility of dosing multiple times in order to treat even the most highly refractory infections,” said Griswold.
The team’s paper, “Globally deimmunized lysostaphin evades human immune surveillance and enables highly efficacious repeat dosing,” was published earlier today by Science Advances. The work was the result of two grants from the National Institutes of Health (NIH) totaling $1.7 million.
The paper details the treatment’s positive results in rabbits, mice with partially-humanized immune systems, and studies with extracted human immune cells. Griswold believes the antibacterial agent could be ready for human clinical trials as soon as 2023.
“This is the first report of a translation-ready deimmunized lysin, and F12 has serious, bonafide clinical potential,” said Griswold.
Further studies of F12 will examine synergy with standard-of-care antibacterial chemotherapies. Preliminary results suggest the combinations are extremely potent and suppress drug-resistance phenotypes.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Drug resistant bacteria
- New antibiotics: Turning to dirt in the fight against drug-resistant bacteriaon October 6, 2020 at 1:28 am
Dirt contains an entire microbial ecosystem, with a wealth of intriguing compounds. And while there are major hurdles between discovering a new drug and using it, scientists are hopeful new techniques ...
- Strengthening Your Child's Microbiomeon October 5, 2020 at 4:26 pm
Lynzie Smith, a 32-year-old mother of two with one on the way, breastfed both her newborns for more than six months and stuck to a low-fat diet high in fruits and vegetables during all of her ...
- Boosting Your Baby’s Bugson October 5, 2020 at 8:21 am
As microbiome science advances, scientists are learning more and more about how everyone can adopt habits that will boost levels of beneficial bacteria in the body while keeping the bad bugs at bay.
- Hospital Acquired Infectionson October 4, 2020 at 1:45 am
The full course of medication prescribed must be completed. If a patient does not complete a course of antibiotics, then some bacteria may survive and develop into a new, drug-resistant strain.
- Bennet, Young Introduce Legislation to Fight Antimicrobial Resistanceon October 2, 2020 at 10:10 am
Bennet, Young Introduce Legislation to Fight Antimicrobial Resistance. Bipartisan Bill Would Encourage Development of Innovative Antibiotics to Treat Resistant Infections and Impr ...
Go deeper with Google Headlines on:
Drug resistant bacteria
Go deeper with Bing News on:
F12 lysin-based antibacterial agent
- Tech Tidbits From Around NHon September 24, 2020 at 8:28 am
one of the most common bacterial pathogens and the single most deadly drug-resistant bacteria in the United States The Dartmouth team has engineered and patented F12, a new lysin-based antibacterial ...
- ContraFect to Present at the 2020 Cantor Global Virtual Healthcare Conferenceon September 9, 2020 at 5:32 am
09, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins ...
- ContraFect to Present at the 2020 Cantor Global Virtual Healthcare Conferenceon September 9, 2020 at 4:54 am
09, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins ...
- ContraFect to Present at the 2020 Cantor Global Virtual Healthcare Conferenceon September 9, 2020 at 12:30 am
About ContraFect: ContraFect is a biotechnology company focused on the discovery and development of direct lytic agents (DLAs ... each year are attributed to antimicrobial-resistant infections.
- ContraFect Corporation (CFRX)on August 16, 2020 at 5:59 am
Initial evaluation of Direct Lytic Agents (DLAs) as potential novel modalities to address ... vitro activity of ContraFect’s next product candidate, CF-370, an engineered lysin targeting Pseudomonas ...